News Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer Staff September 11, 2023 Iframe sync Post navigation Previous: EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023Next: Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference More Stories News TODAY SHOW EXPOSES AI MEDICAL SCAMS TARGETING LIPEDEMA PATIENTS Staff December 6, 2025 Healthcare News Pharmaceutical Queue Ventures Announces Closing of Brokered Private Placement of Subscription Receipts of Custom Fundco Inc. Staff December 5, 2025 Healthcare News Pharmaceutical Queue Ventures Announces Closing of Brokered Private Placement of Subscription Receipts of Custom Fundco Inc. Staff December 5, 2025
